Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality

Neuropsychobiology

Volumn 41, Issue 4, 2000, Pages 181-189

  Saletu, Bernd ^a   Gruber, G ^b   Saletu, M ^b   Brandstatter N ^b   Hauer, C ^b   Prause, W ^b   Ritter, K ^b   Saletu Zyhlarz, G ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Dopamine agonist; First night effect; Noopsyche; Normal controls; Polysomnography; Psychometry; Restless legs syndrome; Ropinirole; Subjective sleep and awakening quality Thymopsyche

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; ROPINIROLE;

ADULT; AGED; AROUSAL; ARTICLE; AUSTRIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FATIGUE; FEMALE; HUMAN; INSOMNIA; LABORATORY; MALE; MOOD; MOTOR ACTIVITY; PATHOGENESIS; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; REACTION TIME; RESTLESS LEGS SYNDROME; SINGLE BLIND PROCEDURE; SLEEP; SLEEP INDUCTION; SLEEP STAGE; WELLBEING;

EID: 0034021514     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026658     Document Type: Article

References (66)

1. Willis T: The London Practice of Physick. London. Bassett and Crook, 1685.
2. Whittmack T: Pathologie und Therapie der Sensibilitäts-Neurosen. Leipzig, Schäfer, 1861.
3. Ekbom KA: Restless legs. Acta Med Scand 1945;158:1-123.
4. Gibb WRG, Lees AJ: The restless legs syndrome. Postgrad Med 1986;62:329-333.
5. Lavigne GJ, Montplaisir JY: Restless legs syndrome and sleep bruxism: Prevalence and association among Canadians. Sleep 1994;17:739-743.
6. Stepanksky R, Schmeiser Rieder A, Holzinger B, Saletu B, Bolitschek J, Zeitlhofer J: Selbsteinschätzung von Parasomnien und Beinunruhe beim Einschlafen - Ergebnisse einer epidemiologischen Untersuchung. Somnologie 1999;3:78-82.
7. Coccagna G, Lugaresi E: Ganznacht-Polygraphien bei Patienten mit schmerzhaften Erkrankungen. EEG EMG Z 1982;13:149-153.
8. Walters AS, the International Restless Legs Syndrome Study Group: Toward a better definition of restless legs syndrome. Mov Disord 1995;10:634-642.
9. Montplaisir J, Godbout R, Pelletier G, Warnes H: Restless legs syndrome and periodic limb movements during sleep; in Kryger MH, Roth T, Dement WC (eds): Principles and Practice of Sleep Medicine. Philadelphia, Saunders, 1989, pp 402-409.
10. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P: Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12:61-65.
11. Akpinar S: Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982;39:739.
12. Akpinar S: Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987;10:69-79.
13. Montplaisir J, Godbout R, Boghen MD, DeChamplain J, Young SN, Lapierre G: Familial restless legs with periodic movements in sleep: Electrophysiological, biochemical, and pharmacological study. Neurology 1985;35:130-134.
14. Montplaisir J, Godbout R, Poirier O, Bedard MA: Restless legs syndrome and periodic movements in sleep: Physiopathology and treatment with L-dopa. Clin Neuropharmacol 1986;9:456-463.
15. Von Scheele C: Levodopa in restless legs. Lancet 1986;ii:426-427.
16. Brodeur C, Montplaisir J, Godbout R, Marinier R: Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: A double-blind, controlled study. Neurology 1988;38:1845-1848.
17. Becker PM, Jamieson AO, Brown WD: Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: Response and complications of extended treatment in 49 cases. Sleep 1993;16:713-716.
18. Guilleminault C, Cetel M, Philip P: Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43:445.
19. Trenkwalder C, Stiasny K, Pollmächter T, Wetter TC, Schwarz J, Kohnen R, Kazenwadel J, Ramm S, Oertel WH: L-dopa therapy of uremic and idiopathic restless legs syndrome: A double-blind crossover trial. Sleep 1995;18: 681-688.
20. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S: A double-blind randomized crossover trial of bromocriptin and placebo in restless legs syndrome. Ann Neurol 1988; 24:455-458.
21. Silber MH, Shepard JW Jr, Wisbey JA: Pergolide in the management of restless legs syndrome: An extended study. Sleep 1997;20:878-882.
22. Early CJ, Allen RP: Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in consecutive series of patients. Sleep 1997;19: 801-810.
23. Wetter TC, Stiasny K, Winkelmann J, Buhlinger A, Brandenburg U, Penzel T, Medori R, Rubin M, Oertel WH, Trenkwalder C: A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-950.
24. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B: Restless legs syndrome improved by pramipcxole: A double-blind randomized trial. Neurology 1999;52:938-943.
25. Ondo W: Ropinirole for restless legs syndrome. Mov Disord 1999;14:138-140.
26. Guilleminaull C, Silvestri R, Mondini S, Coburn S: Aging and sleep apnea: Action of benzodiazepine, acetazolamine, alcohol and sleep deprivation in a healthy elderly group. J Gerontol 1984;39:655-661.
27. Read DJ, Feest TG, Nassim MA: Clonazepam: Effective treatment for restless legs syndrome in uraemia. BMJ 1981;283:885-886.
28. Montagna P, Sassoli de Blanchi L, Zucconi M, Cirignotta F, Lugaresi L: Clonazepam and vibration in the restless legs syndrome. Acta Neurol Scand 1984;69:428-430.
29. Mitler MM, Browman CP, Menn SJ, Gujavarty K, Timms RM: Nocturnal myoclonus: Treatment efficacy of clonazepam and temazepam. Sleep 1986;9:385-392.
30. Boghen D, Lamothe L, Elie R, Godbout R. Montplaisir J: The treatment of the restless legs syndrome with clonazepam: A prospective controlled study. Can J Neurol Sci 1986;13:245-247.
31. Peled R, Lavie P: Double-blind evaluation of clonazepam on periodic leg movements in sleep. J Neurol Neursurg Psychiatry 1987;50: 1679-1681.
32. Hornyak M, Vorderholzer U, Hohagen F, Berger M, Ricmann D: Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: An open pilot study. Sleep 1998;21:501-505.
33. Trzepacz PT, Violette EJ. Sateia MJ: Response to opioids in three patients with restless legs syndrome. Am J Psychiatry 1984;141:993-995.
34. Sandyk R, Bamford CR, Gillman MA: Opiates in the restlegs legs syndrome. Int J Neurosci 1987;36:99-104.
35. Kaplan PW, Allen RP, Buchholz DW, Walters JK: A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and proxyphene. Sleep 1993;16:717-723.
36. Eden RJ, Costall B, Domeney AM, et al: Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
37. Tulloch IF: Pharmacologic profile of ropinirole: A nonergoline dopamine. Neurology 1997;94:58-62.
38. Vidailhet MJ, Bonnet AM, Belal S, Dubois B, Marie C, Agid Y: Ropinirole without levodopa in Parkinson's disease. Lancet 1990;336:316-317.
39. Kapoon R, Pirtosek Z, Frankel JP, et al: Treatment of Parkinson's disease with novel dopamine D2 agonist SK&F 101468. Lancet 1989;i: 1445-1446.
40. Kleedorfer B, Stem GM, Lees AJ, Bottomley JM, Sree-Haran N: Ropinirole (SK&F 101468) in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:10.
41. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D: Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996;19:234-245.
42. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F: Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998;13:39-45.
43. Gálvez-Jiménez N. Khan T: Ropinirole and restless legs syndrome. Mov Disord 1999;14: 890-892.
44. Saletu B, Klösch G, Gruber G, Anderer P, Udomratn P, Frey R: First-night effects on generalized anxiety disorder (GAD)-based insomnia: Laboratory versus home sleep recordings. Sleep 1996;19:691-697.
45. Saletu-Zyhlarz G, Anderer P, Brandstätter N, Dantendorfer K, Gruber G. Mandl M, Ritter K, Zoghlami A, Saletu B: Placebo-controlled sleep laboratory studies on the acute effect of zolpidem on objective and subjective sleep and awakening quality in nonorganic insomnia related to neurotic and stress-related disorder. Neuropsychobiology, in press.
46. Saletu-Zyhlarz G, Anderer P, Berger P, Gruber G, Oberndorfer S, Saletu B: Nonorganic insomnia in panic disorder: Comparative sleep laboratory studies with normal controls and placebo-controlled trials with alprazolam. Hum Psychopharmacol, in press.
47. Saletu M, Anderer P, Saletu B, Hauer C, Mandl M, Oberndorfer S, Zoghlami A, Saletu-Zyhlarz G: Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. II. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology, in press.
48. Rechtschaffen A, Kales A: A Manual of Standardized Terminology, Technique and Scoring System for Sleep Stages of Human Subjects. Los Angeles, Brain Information Service, University of California, 1968.
49. Reynolds CF, Taska LS, Jarret DB, Coble PA, Kupfer DJ: REM latency in depression: Is there one best definition? Biol Psychiatry 1983;18: 849-863.
50. Saletu B, Wessely P, Grünberger J, Schultes M: Erste klinische Erfahrungen mit einem neuen schlafanstossenden Benzodiazepin, Cinolazepam, mittels eines Selbstbeurteilungsbogens für Schlaf- und Aufwachqualität (SSA). Neuropsychiatrie 1987:1:169-174.
51. Von Zerssen D, Koeller DM, Rey ER: Die Befindlichkeitsskala (B-S) - Ein einfaches Instrument zur Objektivierung von Befindlichkeitsstörungen, insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneimittelforschung 1970;20:915-918.
52. Grünberger J: Psychodiagnostik des Alkoholkranken. Ein methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Vienna, Maudrich, 1997.
53. Fünfgeld EW: Vigorimeter: Zur Kraftmessung der Hand und zur Simulationsprüfung. Dtsch Med Wochenschr 1966;49:2214-2216.
54. Saletu B: Psychopharmaka, Gehirntätigkeit und Schlaf. Basel, Karger, 1976.
55. Benca RM, Obermeyer WH, Thisted RA, Gillin JC: Sleep and psychiatric disorders. Arch Gen Psychiatry 1992;49:651-668.
56. Abt K: Descriptive data analysis (DDA) in quantitative EEG studies; in Samson-Dollfus D, Guieu JD, Gotman J, Etevenon P (eds): Statistics and Topography in Quantitative EEG. Amsterdam, Elsevier, 1988.
57. Ferber G, Abt K, Fichte K, Luthringer R: IPEG guideline on statistical design and analysis for pharmacodynamic trials. Neuropsychobiology 1999;39:92-100.
58. Trenkwalder C: Restless legs syndrome, ed 1. New York, Springer, 1998.
59. Saletu M, Hauer C, Anderer P, Gruber G, Oberndorfer S, Mandl M, Popovic R, Saletu B: Tagesmüdigkeit korreliert mit nächtlichen Atmungs- und Arousal-Variablen bei Schlafapnoepatienten: Polysomnographische und EEG-Mapping-Untersuchungen. Wien Klin Wochenschr, in press.
60. Saletu B, Grünberger J: Memory dysfunction and vigilance: Neurophysiological and psychopharmacological aspects. Ann N Y Acad Sci 1985;444:406-427.
61. Edinger JD, Marsh GR, McCall WV, Erwin CW, Liniger AW: Sleep variability across consecutive nights of home monitoring in older mixed DIMS patients. Sleep 1991;14:13-17.
62. Saletu-Zyhlarz G, Anderer P, Hassan-Abu Bakr M, Gruber G, Saletu B: Nonorganic insomnia in depression: Comparative sleep laboratory studies with normal controls and placebo-controlled trials with trazodone, in preparation.
63. Saletu-Zyhlarz G, Anderer P, Hassan-Abu Bakr M, Gruber G, Saletu B: Nonorganic insomnia in dysthymia: Comparative sleep laboratory studies with normal controls and placebo-controlled trials with trazodone, in preparation.
64. Akiskal HS, Lemmi H, Dickson H, King D, Yerevanian B, Van Valkenburg C: Chronic depression. 2. Sleep EEG differentiation of primary dysthymic disorders from anxious depression. J Affect Disord 1984;6:287-295.
65. Monti JM, Hawkins M, Jantos H, D'Angelo L, Fernández M: Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in rats. Psychopharmacology 1988;95:395-400.
66. Saletu M, Anderer P, Saletu B, Hauer C, Gruber G, Mandl M, Ritter K, Zoghlami A, Saletu-Zyhlarz G: Sleep laboratory studies on periodic limb movement patients as compared with normals and acute effects of ropinirole. Hum Psychopharmacol, in preparation.